Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2 (Q69333914)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

title

Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

main subject

hepatocellular carcinoma

1 reference

T Ichida

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

K Higuchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

K Arakawa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

H Ohta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

K Sugiyama

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

M Miyagiwa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

A Nohzawa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

T Satoh

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

H Sasaki

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

F Ichida

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

publication date

1 January 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

30 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

volume

23 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

30 September 2019

page(s)

S45-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2538266%20AND%20SRC:MED&resulttype=core&format=json

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

30 September 2019

cites work

1 reference

12 December 2020

Passive Immunotherapy of Cancer in Animals and Man

1 reference

12 December 2020

Interleukin-2 augments natural killer cell activity

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

12 December 2020

Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells

1 reference

12 December 2020

Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma

1 reference

12 December 2020

T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

The fate of interleukin-2 after in vivo administration

1 reference

12 December 2020

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

1 reference

12 December 2020

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

12 December 2020

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2

1 reference

12 December 2020